This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Protalix BioTherapeutics (PLX) Jumps: Stock Rises 9%
by Zacks Equity Research
Protalix BioTherapeutics(PLX) saw its shares rise 9% on the day.
uniQure (QURE) in Focus: Stock Moves 11.9% Higher
by Zacks Equity Research
uniQure (QURE) saw its shares rise nearly 12% on the day.
Exelixis (EXEL) Looks Good: Stock Adds 17.2% in Session
by Zacks Equity Research
Exelixis (EXEL) was a big mover last session, as the company saw its shares rise more than 17% on the day amid huge volumes.
Five Prime Therapeutics, Inc. (FPRX) Jumps: Stock Rises 6.2%
by Zacks Equity Research
Five Prime Therapeutics, Inc. (FPRX) saw its shares rise over 6% on the day.
Athersys (ATHX) in Focus: Stock Moves 7.2% Higher
by Zacks Equity Research
Athersys (ATHX) shares rose more than 7% in the last trading session, amid huge volumes.
Rexahn Pharmaceuticals (RNN) in Focus: Stock Moves 6.1% Higher
by Zacks Equity Research
Rexahn Pharmaceuticals (RNN) was a big mover last session, as the company saw its shares rise more than 6% on the day.
Company News For Sep 27, 2017
by Zacks Equity Research
Companies in the news are: RHT,DRI,CCL,AXON
Axovant Sciences (AXON) Stock Crashed Over 70%: Here's Why
by Madeleine Johnson
On Tuesday, shares of biopharmaceutical company Axovant Sciences Ltd. (AXON) have crashed, and the stock is currently down over 70% to $6.72 per share in late-morning trading after it said that its experimental Alzheimer's drug failed a key late-stage trial.
Options Traders Expect Huge Moves in Axovant Sciences (AXON) Stock
by Zacks Equity Research
Surging implied volatility makes Axovant Sciences (AXON) Stock lucrative to the option traders.
Axovant Sciences Ltd. (AXON) Jumps: Stock Rises 7.2%
by Zacks Equity Research
Axovant Sciences Ltd. (AXON) was a big mover last session, as the company saw its shares rise over 7% on the day.
Are Options Traders Betting on a Big Move in Axovant Sciences (AXON) Stock?
by Zacks Equity Research
High level of implied volatility makes Axovant Sciences (AXON) Stock lucrative to the option traders.
Options Traders Expect Huge Moves in Axovant Sciences (AXON) Stock
by Zacks Equity Research
Axovant Sciences (AXON) needs Investors to pay close attention to the stock based on moves in the options market lately.
Implied Volatility Surging for Axovant Sciences (AXON) Stock Options
by Zacks Equity Research
Axovant Sciences (AXON) warrants investors' attention based on moves in the options market lately.
Implied Volatility Surging for Axovant Sciences (AXON) Stock Options
by Zacks Equity Research
Investors in Axovant Sciences Ltd. (AXON) need to pay close attention to the stock based on moves in the options market lately.
Arena Pharmaceuticals (ARNA) Posts Q1 Loss, Revenues Down
by Zacks Equity Research
Arena Pharmaceuticals, Inc. (ARNA) reported loss of 9 cents per share in the first quarter of 2017, same as in the year-ago period but wider than the Zacks Consensus Estimate of a loss of 8 cents.
Implied Volatility Surging for Axovant Sciences (AXON) Stock Options
by Zacks Equity Research
Axovant Sciences (AXON) warrants investors' attention based on moves in the options market lately.
Axovant Sciences (AXON) Shows Strength: Stock Jumps 9.2%
by Debasmita Banerjee
Axovant Sciences Ltd. (AXON) shares rose a little above 9% in the last trading session.
Is the Options Market Predicting a Spike in Axovant Sciences (AXON) Stock?
by Zacks Equity Research
Options traders are pricing in a big move for Axovant Sciences (AXON) shares as it has huge implied volatility.
The Zacks Analyst Blog Highlights: Incyte, Prothena, Acorda Therapeutics and Axovant Sciences
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Incyte, Prothena, Acorda Therapeutics and Axovant Sciences
Implied Volatility Surging for Axovant Sciences (AXON) Stock Options
by Zacks Equity Research
Axovant Sciences (AXON) warrants investors' attention based on moves in the options market lately.